NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

"Somewhere between 35-80% of people with PMOS experience insulin resistance, making weight management important." ...

"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.

Persistent fatigue, sugar cravings and irregular periods are often blamed on stress or a hectic lifestyle. However, doctors ...

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

"If you are diagnosed with Polyendocrine Metabolic Ovarian Syndrome, it doesn't mean that you are destined to have poor ...

“For anyone quietly carrying this heartbreak, you’re not alone.” ...

New science links poor sleep habits to severe long-term health risks. Five leading wellness experts break down the steps you ...

A growing body of epidemiological evidence points to an inverse relationship between cancer and Alzheimer’s disease (AD): individuals with a cancer ...

Multiple guidelines recommend ongoing breast cancer risk assessment for women, beginning by age 25, to identify individuals at increased risk who may need enhanced breast cancer screening. 1,2. A risk ...